Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Epidemiology

Abstract 3010: Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study

Gry S. Haaland, Ragnhild S. Falk, Oddbjørn Straume and James B. Lorens
Gry S. Haaland
University of Bergen, Bergen, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ragnhild S. Falk
University of Oslo, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oddbjørn Straume
University of Bergen, Bergen, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Lorens
University of Bergen, Bergen, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-3010 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

BACKGROUND

Evidence shows that the vitamin K-antagonist warfarin, a popular anti-coagulant in clinical use for decades, has anti-tumor activity. This is recently attributed to disruption of post-translational modification of Gas6, the common ligand of the Axl receptor tyrosine kinase family. Gas6-Axl signaling is associated with malignancy and is required for tumoriogenesis and progression in several preclinical cancer models. Warfarin is shown to inhibit Axl signaling-dependent malignant traits and enhance anti-tumor immune responses at doses that do not achieve anticoagulation. The objective of this study is to investigate the association between warfarin use and cancer incidence in a large unselected Norwegian cohort. Our results reveal a remarkable reduction in cancer incidence associated with warfarin use across a wide range of tumor types.

METHODS

A cohort selected from the Norwegian population registry included all persons born between 1924-1954, living in Norway 2006-2012 (n=1 256 725). We cross-referenced this cohort using the unique Norwegian National ID Number to: 1) the Cancer Registry of Norway and retrieved information on all cancer cases 2006-2012; 2) information on filled warfarin prescriptions (ATC: B01AA03) from the Norwegian Prescriptions Database (2004-2012). Warfarin-use was defined > 6 months and minimum 2 years between first warfarin prescription and cancer diagnosis. We also performed a subgroup analysis on persons prescribed warfarin for atrial fibrillation/flutter (n=33 313) compared to non-users. Mantel-Haenzel method was used to calculate the incidence rate ratio (IRR), adjusting for sex and age.

RESULTS

In this cohort, 92 942 persons were classified as warfarin users, and we observed 132 687 cancer cases in the 7-year study period. We observed a significantly lower sex and age-adjusted risk for cancer development across all malignancy types in the warfarin user group compared to the non-user group (IRR: 0.842, 95% CI, 0.824-0.861). The association was similar among many cancers including major types (prostate IRR: 0.687,95% CI 0.653-0.722; lung IRR: 0.801, 95% CI 0.749-0.856; breast IRR: 0.903, 95% CI 0.817-0.998). Given the expected confounding effect of thrombotic disease on cancer incidence, we conducted a subgroup analysis among patients prescribed warfarin for atrial fibrillation/flutter (AF-group), a subgroup with reduced comorbidity. Warfarin users in the AF-group showed a stronger overall cancer risk reduction (IRR: 0.619, 95%CI 0.592-0.646), including all major cancer types, particular lung cancer. (Prostate, IRR: 0.604, 95%CI 0.552-0.662; Lung IRR: 0.391, 95%CI 0.332-0.460; Breast IRR: 0.720, 95%CI 0.594-0.871)

CONCLUSION

We show that warfarin use is associated with a broad cancer protective effect in a large unselected patient cohort. Subgroup analysis of arrhythmia patients to reduce confounders reinforced the notion that warfarin exerts important anti-tumor effects.

Citation Format: Gry S. Haaland, Ragnhild S. Falk, Oddbjørn Straume, James B. Lorens. Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3010. doi:10.1158/1538-7445.AM2017-3010

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 3010: Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 3010: Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study
Gry S. Haaland, Ragnhild S. Falk, Oddbjørn Straume and James B. Lorens
Cancer Res July 1 2017 (77) (13 Supplement) 3010; DOI: 10.1158/1538-7445.AM2017-3010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 3010: Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study
Gry S. Haaland, Ragnhild S. Falk, Oddbjørn Straume and James B. Lorens
Cancer Res July 1 2017 (77) (13 Supplement) 3010; DOI: 10.1158/1538-7445.AM2017-3010
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Epidemiology

  • Abstract SY32-02: Genetic architecture of cancer and other complex diseases: Lessons learned and future directions
  • Abstract SY07-04: Diet and xenobiotic-metabolizing enzymes: Learning from controlled feeding studies in humans
  • Abstract SY08-01: Cancer in immunosuppressed populations: Epidemiologic clues to causation
Show more 3

Oral Presentations - Proffered Abstracts

  • Abstract LB-338: A critical evaluation of genomic data sharing: Barriers to accessing pediatric cancer genomic datasets: a Treehouse Childhood Cancer Initiative experience
  • Abstract LB-105: Characterization of total mutational burden in the GENIE cohort: Small and large panels can provide TMB information but to varying degrees
  • Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study
Show more 3

Proffered Oral Presentations - Cancer Epidemiology and Prevention

  • Abstract 3007: Tobacco smoking, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project
  • Abstract 3012: Long-term aspirin use and total and cancer-specific mortality
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement